The patient underwent kidney biopsy. Despite the mild renal lab’ alterations, kidney biopsy showed a severe intra- and extra-capillary glomerulonephritis Class IV ISN/RPS with an activity index of 15 ...

The therapeutic armamentarium of the lupologist is expanding, notably when faced with one of the most frequent severe systemic lupus erythematosus (SLE) organ manifestation: Lupus nephritis (LN).

1 More than 1.5 million people develop one of the most dangerous manifestations of SLE: lupus nephritis (LN), characterized ... who should take the lead in LN management: nephrology or rheumatology.

Objective: Examine strategies for early diagnosis/screening, updated treatment guidelines, and treatment and payer considerations to optimize lupus nephritis management and address patient access ...

Panelists discuss the updated treatment recommendations for lupus nephritis in the Kidney Disease Improving Global Outcomes and European Alliance of Associations for Rheumatology guidelines ...

Lupus nephritis (kidney involvement in lupus) is a relatively common - and perhaps the most important - complication of systemic lupus erythematosus (SLE), with potentially serious consequences for ...

Background Lupus Nephritis (LN) is an immune-complex mediated glomerulonephritis affecting up to 60% of all SLE patients during the disease course. A kidney biopsy is indicated in SLE patients when ...

More importantly, lupus nephritis (LN) is a major cause of morbidity increasing substantially the ... Of note, the all-cause and cause-specific SMR significantly decreased over time, likely reflecting ...

After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis.